Iricryn (Bimatoprost)

Bimatoprost binds to prostaglandin F (FP) receptors in the eye, increasing the uveoscleral outflow of aqueous humor. This enhanced outflow reduces intra‑ocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension management.

The dosing regimen for Iricryn is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and frequency should follow the prescriber’s instructions.

Safety data for bimatoprost in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, so it should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under medical supervision.

To order Iricryn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iricryn (bimatoprost) is a prostaglandin analog, a class known for potent intra‑ocular pressure reduction with once‑daily dosing. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogs often achieve greater pressure lowering and have a different side‑effect profile, such as increased eyelash growth.

Iricryn should be stored at room temperature, below 25 °C. Keep the bottle tightly closed, protect it from light and moisture, and do not freeze. Discard any solution that appears discolored or contains particles.

Iricryn is administered as an ophthalmic solution. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place one drop into the conjunctival sac of the prescribed eye(s). Close the eye gently and avoid blinking excessively.

Serious risks include severe eye inflammation (uveitis), allergic reactions with swelling or rash, paradoxical increase in intra‑ocular pressure, corneal edema, and rare cases of vision loss. Patients should seek immediate medical attention if they experience significant pain, redness, or visual changes.

Iricryn should not be used by individuals with active ocular infections or inflammation, known hypersensitivity to bimatoprost or any component of the formulation, or by patients for whom prostaglandin analogs are contraindicated. A healthcare professional should evaluate suitability before initiating therapy.